Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top California based President operating in the Health Care space. If you think a President is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Emily Reuter
Vice President of Strategy and Operations of Color
Emily Reuter is the Vice President of Strategy and Operations at Color.
Follow Emily Reuter:
About Color: Color is a population health technology company that enables the delivery of advanced healthcare through clinical genetics.
Sean Bohen
Executive Vice-President, Global Medicines Development and Chief Medical Officer of AstraZeneca
Sean was appointed Executive Vice-President, GMD in September 2015 and leads our global late-stage development organisation for both small molecules and biologics. He is also the Company’s Chief Medical Officer and is responsible for patient safety across the entire AstraZeneca and MedImmune portfolio. He joined AstraZeneca from Genentech, where he held a number of senior leadership roles across various therapy areas and was most recently Senior Vice President of Early Development. Before joining Genentech, Sean was a Clinical Instructor in Oncology at Stanford University School of Medicine, a research associate at the Howard Hughes Medical Institute and a postdoctoral fellow at the National Cancer Institute. He is a graduate of the University of Wisconsin and later earned his doctorate in biochemistry and his medical degree at the University of California, San Francisco.
Follow Sean Bohen:
About AstraZeneca: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Kris Snodgrass
Vice President of Talent of Norwest Venture Partners
Follow Kris Snodgrass:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Ellie Javadi
Vice President | Head of Communications, PR, Marketing of Norwest Venture Partners
Follow Ellie Javadi:
About Norwest Venture Partners: Norwest is a global venture capital and growth equity investment firm that specializes in venture and growth equity companies.
Raymond H. Diradoorian
Executive Vice President of Allergan
Mr. Diradoorian has been Executive Vice President, Global Technical Operations since February 2006. From April 2005 to February 2006, Mr. Diradoorian served as Senior Vice President, Global Technical Operations. Since February 2001, Mr. Diradoorian served as Vice President, Global Engineering and Technology. Mr. Diradoorian joined Allergan in July 1981. Prior to joining Allergan, Mr. Diradoorian held positions at American Hospital Supply and with the Los Angeles Dodgers baseball team. Mr. Diradoorian received a Bachelor of Science degree in Biological Sciences from the University of California, Irvine and a Master of Science degree in Technology Management from Pepperdine University.
Follow Raymond H. Diradoorian:
About Allergan: Allergan is a global pharmaceutical company.
Ronald Hutton
Vice President, Treasurer of Bio-Rad Laboratories
Follow Ronald Hutton:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
James Stark
Vice President, Corporate Controller of Bio-Rad Laboratories
Follow James Stark:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Mike Crowley
Executive Vice President, Global Commercial Operations of Bio-Rad Laboratories
Follow Mike Crowley:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Timothy Ernst
Executive Vice President, General Counsel & Secretary of Bio-Rad Laboratories
Follow Timothy Ernst:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Rachel Gollub
Vice President of Benefitter Technology of UnitedHealth Group
Founder at Benefitter
Follow Rachel Gollub:
About Benefitter, HealthMarkets, UnitedHealth Group: UnitedHealth Group is a healthcare company that offers insurance products and services for everyone.
Maynd Jolly
Vice President Strategic Corporate Accounts of Siemens Healthineers
Follow Maynd Jolly:
About Siemens Healthineers: Siemens Healthineers is a healthcare technology company that provides diagnostic and therapeutic products and services.
Chris Fuller
Vice President of Informatics of Caribou Biosciences
Follow Chris Fuller:
About Caribou Biosciences: Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Alex Aravanis
Chief Technology Officer & Senior Vice President of Illumina
Follow Alex Aravanis:
About Illumina: Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Craig Ciesla
Vice President Advanced Engineering of Illumina
Follow Craig Ciesla:
About Illumina: Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Richard Klausner
Senior Vice President & Chief Medical Officer of Illumina
Richard Klausner joined Illumina in September 2013 as Senior Vice President and Chief Medical Officer. Richard is responsible for Illumina’s strategies for advancing genomics into clinical medicine and public health. He is also part of Illumina’s executive management team, which is responsible for directing all aspects of company strategy, planning and operations. Richard is a Scientific Advisor at Cyterix Pharmaceuticals Inc. He co-founded Pathwork Diagnostics, Inc. (Alternative name is Predicant Biosciences Inc.) in 2002. He serves as the Managing Partner at The Column Group LLC. He served as the Chairman of the Strategic Development and Scientific Advisory Council at Sanofi from March 1, 2011 to January 2013. Richard serves as the Chairman of the National Science Education Standards Projects of the National Academy of Science, overseeing the first comprehensive process to provide a vision of scientific literacy in the American educational system and the criteria required to achieve it. He served as Co-Chairman of the Scientific Advisory Board and Scientific Advisor at Aragon Pharmaceuticals, Inc. He served as an Executive Director for Global Health at the Bill & Melinda Gates Foundation. Richard served as the President at the American Society of Clinical Investigation. He served as an Advisor to the President of the Academies for counter-terrorism, and a Liaison to the White House Office of Science and Technology Policy. From 1979 to 1981, he worked at NIH in National Cancer Institute’s (NCI) Laboratory of Mathematical Biology. He served as a Director of Pathwork Diagnostics, Inc. and Immune Design Corp. He served as Director of 3-V Biosciences, Inc. He served as a Director of NCI from August 1, 1995 to 2001. He serves as a Member of Scientific Advisory Board at NGM Biopharmaceuticals, Inc., Immune Design Corp., Constellation Pharmaceuticals and Audax Health Solutions. Richard served as a Distinguished Scientific and Strategic Advisor of Aveo Pharmaceuticals, Inc. Richard currently sits on the board of Juno Therapeutics. He is also the Chief Strategy Advisor for USAID. He is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. He served as a Member of Scientific Advisory Board at Infinity Pharmaceuticals, Inc., Igenica, Inc. and T2 Biosystems, Inc. Rick holds an M.D. from Duke Medical School.
Follow Richard Klausner:
About Audax Health Solutions, Illumina, Pathwork Diagnostics: Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Jay Flatley
President & CEO of Illumina
Jay was appointed President and CEO of Illumina in 1999 and oversaw the company’s expansion into the whole genome sequencing area with the acquisition of Solexa in 2006, and more recently into diagnostics and consumer sequencing. Under his leadership, Illumina has been named multiple times to the Deloitte & Touche Fast 50 and Fast 500 lists, as well as to the Forbes 25 Fastest-Growing Tech Companies (2007, 2009 and 2010), the Fortune 100 Fastest-Growing Companies (2010 and 2011) lists, and recognition by MIT Technology Review as the World’s Smartest Company in 2014. Previously, Jay served as President and Chief Executive Officer of Molecular Dynamics. As a co-founder and member of the board of directors for Molecular Dynamics he led the company to its initial public offering in 1993. He helped Molecular Dynamics develop and launch over 15 major instrumentation systems, including the first capillary-based DNA sequencer. Currently, he is an Advisory Board member for UC San Diego’s Moores Cancer Center, and a member of the Board of Directors at Coherent, Denali, and Illumina, Inc. Jay received a B.A. in economics from Claremont McKenna College and a B.S. and M.S. (summa cum laude) in industrial engineering from Stanford University.
Follow Jay Flatley:
About Illumina: Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Austin Harkness
Executive Vice President, Operations of Honor
Follow Austin Harkness:
About Honor, Sunoco – Stores: Honor is a senior care network and technology platform that offers personalized care to improve the in-home care experience.
Jim Sellors
President, Avery North America of CCL Industries
Sellors spent his formative business career at CCL in the Finance function and rejoined the Company in 2002 as Vice President and General Manager of CCL Label Canada eventually assuming the role of Group Vice President of CCL Label Healthcare and Specialty, North America and Australia in 2010. Sellors was promoted to President of Avery North America in July 2013. Prior to rejoining CCL, he was the Vice President of Marketing for the Rubbermaid Closet Products division of Newell Rubbermaid. Sellors holds a Bachelor of Commerce degree from Queen’s University at Kingston, Ontario.
Follow Jim Sellors:
About CCL Industries: CCL is the largest label company in the world and provides innovative solutions.
Andy Iseli
Vice President and General Manager, CCL Tube of CCL Industries
Andy Iseli is a Vice President and General Manager, CCL Tube at CCL Industries.
Follow Andy Iseli:
About CCL Industries: CCL is the largest label company in the world and provides innovative solutions.
Zhen Li
Founder, President & CEO of ADARx Pharmaceuticals
Dr. Li is a co-founder of ADARx and a successful executive with more than two decades of diverse experience in research and development in the pharmaceutical and biotech industries. Prior to ADARx, Dr. Li served as Senior VP at Arrowhead Pharmaceuticals where she led the discovery and non-clinical development of Arrowhead’s delivery platform and multiple product candidates that are now in clinical studies. Previously, Dr. Li was a director at Merck, leading a team dedicated to siRNA development. Dr. Li received her Ph.D. in Chemistry and Chemical Biology from Harvard University, and her B.S. from Peking University.
Follow Zhen Li:
About ADARx Pharmaceuticals: ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
Andrew Song
President and Co-Founder of Whisper
Andrew Song is the President and Co-Founder at Whisper.
Follow Andrew Song:
About Whisper: Whisper develops AI-enabled, updateable hearing aids for people with hearing loss.
Kim D. Blickenstaff
President and Chief Executive Officer of Tandem Diabetes Care
Kim joined Tandem in August 2007, bringing more than 30 years of healthcare experience in finance, marketing management, sales and strategic planning. Prior to joining Tandem, he was Chairman, Chief Executive Officer and co-founder of Biosite Incorporated, a medical diagnostic company that was acquired by Inverness Medical Innovations for $1.8 billion in June 2007. Prior to founding Biosite, he held various finance, operations, research management, sales management, strategic planning and marketing positions with Hybritech Incorporated and Baxter Healthcare. Kim has been active in the medical device and diagnostics industry over the last 12 years, serving on the board of directors for innovative, young healthcare companies such as SenoRx and MediVation Incorporated. He holds a Masters of Business Administration from Loyola University Chicago’s Graduate School of Business.
Follow Kim D. Blickenstaff:
About Tandem Diabetes Care: Tandem Diabetes Care develops medical devices for the treatment of diabetes offering diabetic insulin pumps for adults and children.
Paul Molloy
President & CEO of ClearFlow
Paul has over twenty years experience of operations, executive management and Board work at public, private and VC funded medical device companies. Two IPO’s at previous companies, particularly as President & Managing Director orchestrating LMA’s successful 2005 SGX listing at a market capitalization of >$300m. LMA was recently acquired by Teleflex in a process that he brokered. Paul was a practicing CRNA until he joined Datascope Corp in NJ in 1989, obtaining his MBA from the University of Chicago’s Booth School of Business and rising through executive positions with leading medical device firms to CEO level in successive start ups, most recently completing the sale of VasoNova to Teleflex Inc. He has extensive global industry connections and has traveled, lived and worked in Asia, Europe and the USA, including substantial experience setting up and managing operations in Australia, Germany, Switzerland, Singapore, China, Japan, India and Latin America as well as serving on the Board of those local subsidiaries.
Follow Paul Molloy:
About ClearFlow: ClearFlow is a medical device company developing technologies to solve clinical problems associated with obstructed catheters.
Rod Burreson
Founder and President of Roex
Rod Burreson, the company’s founder and President, is a former athlete and body builder who has experienced a myriad of ailments and injuries resulting from these activities. Mr. Burreson became committed to finding and developing non-pharmaceutical solutions to improve his own quality of life. Not content with the current products and formulas on the market, Mr. Burreson, through education, research, and the collaboration of many of the finest professionals in their field, began to develop the highest quality formulas and comprehensive products that would meet his own specific health needs. Recognizing the tremendous health benefits he experienced, Rod realized that many other people could benefit from these types of products as well. Armed with the antioxidant (PC-95) he imported from Europe, Rod subsequently formed Roex Inc. in 1994, a company dedicated to finding solutions for some of the many problems associated with aging and nutritional deficiency. Since introducing PC-95, Roex has steadily added products to its line. Today, thanks to you, our loyal customers, Roex is one of the fastest growing companies in the nutritional supplement industry.
Follow Rod Burreson:
About Roex: Roex is one of the fastest growing companies in the nutritional and dietary supplement industry.
Martin G. Reese
Co-Founder, Chief Executive Officer & President of Fabric Genomics (formerly Omicia)
Martin Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Omicia, Martin Reese served as Vice President of Discovery Informatics for ValiGen. Prior to this, Martin Reese co-founded Neomorphic, where he served as President and Chief Scientific Officer. The human genome annotation software that Martin Reese developed at Neomorphic, provided the foundation for the successful commercialization of microarrays by Affymetrix. During his career Martin Reese has been actively involved in community-wide assessments of genome annotation. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project, which provided the essential proof-of-concept platform for “shotgun” sequencing technology. At the Lawrence Berkeley National Laboratories Martin Reese developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of Hohenheim, Germany and the University of California, Berkeley.
Follow Martin G. Reese:
About Fabric Genomics (formerly Omicia): Global healthcare platform for genomics-driven precision medicine. Fabric’ proven AI algorithms power genomic insights.
Greg Gosch
Co-Founder, President, & CEO of ChromaCode
Greg has over 20 years of management experience in the molecular diagnostics and nucleic acids research fields. He spent 9 years at Luminex, when the company grew revenues from $30 million to over $200 million. He held multiple roles including VP of Sales and Marketing, where he was responsible for global commercial operations, and VP/GM of Biosciences, where was responsible for developing novel instrument and assay products for gene expression, microRNA, newborn screening and Alzheimer’s disease. Prior to Luminex, Greg served in various commercial leadership roles at Nanogen, Chiron Diagnostics and Bio-Rad. He has a bachelors degree in molecular, cellular and developmental biology from the University of Colorado and dual masters degrees in business and healthcare administration from the University of Minnesota.
Follow Greg Gosch:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Michael Scott Mann
President of Endonovo Therapeutics
Michael Scott Mann has over 30 years experience in merger and acquisitions and operational management. In 2008 Mr. Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics, Inc,. and led the company to become listed on the OTCBB in 2012. From January 2003 to April, 2011, Mr. Mann was the Founder, President and Chief Executive Officer of U.S. Debt Settlement, Inc. (USDS), a Frankfurt listed company, where he implemented a growth by acquisition strategy successfully acquiring numerous companies. From January 2002 to July 2003, Mr. Mann was the Chief Executive Officer of Shared Vision Capital, a boutique investment banking firm that assisted emerging companies with early seed capital and bridge loans. Earlier still, from October 1998 to December 2001, Mr. Mann was the Vice President of Investor Relations for JuriSearch.com, an online legal research platform. During his tenure with JuriSearch.com, Mr. Mann was directly responsible for funding the company’s growth and development. In addition, Mr. Mann founded Universal Pacific Communications, a privately owned telecommunications company. Under his leadership as President, Universal Pacific developed a fiber optic disaster recovery telecommunications network, designed for and successfully marketed to Fortune 1000 companies.
Follow Michael Scott Mann:
About Endonovo Therapeutics: Endonovo Therapeutics is a biotechnology company developing off-the-shelf regenerative products.
John Doyle
Co-CEO , President & COO of Castlight Health
John leads the finance, human resources and corporate development teams. John joined Castlight after serving as chief operating officer at Achaogen, a biopharmaceutical company. In that role, John managed business development, finance, information technology, and business strategy. Previously, John was vice president of finance and corporate planning at Genentech, Inc. John received an MBA from the University of California, Berkeley, and a BS in business administration from California Polytechnic State University, San Luis Obispo. He is a member of the 2012 Class of Henry Crown Fellows at the Aspen Institute and serves on the Achoagen board of directors.
Follow John Doyle:
About Castlight Health: Castlight Health provides a healthcare navigation platform with resources for benefits, and vendors.
Amit Vohra
Co-Founder, President & CEO of Promaxo
Promaxo is led by Dr. Amit Vohra who is a serial entrepreneur, business strategist and advisor to several healthcare and technology startups. Amit is a Partner in Advanced Biopharma Consulting, a management consultancy offering strategic business development and commercialization services in the life sciences space. He also serves as an advisor to Cricking, MedDx and HealthyX and a strategy consultant to Precision Biopsy and Weinberg Medical Physics. Prior to Promaxo, Amit was the CEO/President of Convergent Life Sciences wherein he took a MRI-US fusion product, for targeted laser ablation of soft tissue cancer, through FDA clearance within 18 months of Company formation. Previously, as VP of Strategy and Operations at Eigen, he led the development and successful commercialization of two class II medical devices in the prostate biopsy space. In 2009, Amit co-founded Navya Biomedical Technologies, a biotechnology company using proprietary polyhydroxy fullerenes (PHF) for non-invasive imaging and destruction of solid tumors. Amit has a Doctorate in Mechanical Engineering from University of Florida, and an Executive MBA (Fuqua Scholar) from Duke University’s Fuqua School of Business.
Follow Amit Vohra:
About 8chili, Neuro42, Promaxo, TriOcula Technologies: Promaxo is commercializing customer-centric MRI systems and robotic guidance tools for live diagnosis and treatment in a physician’s office.
Irv Edwards
Founder & President of Emergent Medical Associates
Dr. Irv Edwards obtained his Bachelor’s Degree from McGill University and his Medical Degree from the University of Calgary in Alberta, Canada. He came to Los Angeles to pursue his interest in Emergency Medicine and interned at Los Angeles County Hospital. After his internship, Dr. Edwards completed his residency in Emergency Medicine at Harbor UCLA Medical Center. Following his residency, Dr. Edwards pursued private practice at a variety of hospital sites in Los Angeles and Orange Counties including Chino Valley Medical Center, Encino-Tarzana Regional Medical Center, La Palma Intercommunity Hospital, Mission Community Hospital, Montclair Hospital Medical Center, Olympia Medical Center, Sherman Oaks Hospital, and Valley Presbyterian Hospital. He was the Director of Performance Improvement at Mission Community Hospital from 1998 – 2003 and he currently serves as the Director of Case Management at Mission Community Hospital and as the Chief of Staff at Chino Valley Medical Center. He is the Director of Emergency Services at Chino Valley Medical Center, Encino-Tarzana Regional Medical Center, Mission Community Hospital, and Montclair Hospital Medical Center. In 1989, Dr. Edwards founded Emergent Medical Associates and has served as its President since inception. Since 2001, Dr. Edwards has been a dedicated member of CAL/ACEP and he currently sits on their Executive Board. He served as its President from 2005-2006.
Follow Irv Edwards:
About Emergent Medical Associates: Emergent Medical Associates is a provider of emergency care and episodic care management services to patients.
Agatha Martindale
Vice President and Global Finance of Rakuten Medical
Follow Agatha Martindale:
About BUILTBYGIRLS, Rakuten Medical, Rakuten Medical: Rakuten Medical is a biotechnology company that develops therapies to treat cancer.
Christine Lemke
Co-Founder & President of Evidation Health
As Chief Product Officer, Christine leads product management and development at Evidation Health. Previously, Christine co-founded and led The Activity Exchange, an insight and personalization platform that helps healthcare companies deliver the right digital interventions and incentives to consumers to help them achieve sustainable behavior change. Prior to her work in healthcare, Christine was the co-founder and Chief Operating Officer of Sense Networks, developers of the first machine learning platform for mobile phone activity data (exited to YP.com). She has also held roles at 3iGroup (Paris), Microsoft XBOX and co-founded Chicago-based Channel IQ, a product analytics platform. Christine has a BA from the University of Washington and an MBA from HEC Paris.
Follow Christine Lemke:
About Evidation Health, Evidation Health: We enable and empower everyone to participate in better health outcomes.
Uday Kumar
Founder, President, CEO, and Board Member of Element Science
Co-Founder & Board Member at Sympara Medical – Dr. Uday N. Kumar, a cardiologist and cardiac electrophysiologist by training.
Follow Uday Kumar:
About Element Science, Stanford University, Sympara Medical: Element Science is a medical device and digital health start-up that develops lifesaving wearable solutions.
Hira Thapliyal
Founder, President & CEO of Aneumed
Hira Thapliyal is the founder, president & CEO of AneuMed, Inc.AneuMed is an early stage company engaged in developing devices for the treatment of various ailments affecting the human cardiovascular system. Prior to that, Dr. Thapliyal was the co-founder, president & CEO of VytronUS, Inc., a development stage company working on products for treatment of cardiac arrhythmias. Currently, VytronUS is conducting human clinical trials for its products. Before that, Hira was the co-founder, president & CEO of Tescient, Inc. Tescient was focused in developing products aimed at tissue regeneration and wound healing in human body. Tescient prototype products did not perform well in early animal tests, so Dr. Thapliyal closed Tescient and returned 60% of the invested capital back to the investors. Prior to Tescient, Dr. Thapliyal co-founded ArthroCare Corp (NASDAQ: “ARTC”) in 1993, and served its president & CEO and took the company public in 1996. ArthroCare was recently acquired by Smith & Nephew for $1.7 billion. ArthroCare markets products in the field of arthroscopy, ENT, spine, skin, and wound healing. Before ArthroCare, Hira served as the president of MicroBionics, a company developing products for continuous measurements of blood parameters in critically ill patients. Before MicroBionics, Hira co-founded and served as the president of CardioVascular Imaging Systems (NASDAQ: “CVIS”) which developed and marketed an ultrasound based imaging system, Intravascular Ultrasound (‘IVUS’), for the human blood vessels. CVIS went public and was later acquired by Boston Scientific (“BSX”). Prior to that, Hira served as the Vice President of Devices for Vascular Interventions (DVI) which developed and marketed products for removal of plaque form inside on the diseased arteries. DVI was acquired by Eli Lilly in 1989. Prior to DVI, Dr. Thapliyal held engineering and management positions at Oximetrix, Inc., Amdahl, and Corning. Dr. Thapliyal holds a BSEE degree from Washington State University, a MSEE from University of Idaho, and a PhD degree in Materials Science & Engineering from Cornell University. Hira has received numerous awards, and currently serves as an advisor to the Stanford-India Biodesign Program at Stanford University. Dr. Thapliyal also served as a judge for the Entrepreneur of the Year award at Earnst & Young. Dr. Thapliyal currently holds over 193 issued US and International patents for various medical devices.
Follow Hira Thapliyal:
About Aneumed, VytronUS: Aneumed is a biotechnology company based in California, United States.
Jonathan Congdon
President & Co-founder of Beachbody
Jonathan Congdon is the CEO and Founder of Openfit.
Follow Jonathan Congdon:
About Beachbody, Openfit: Beachbody has developed and offering an in-home fitness and weight loss solutions.
Helene Klein
Executive-Vice President, People of Beachbody
Follow Helene Klein:
About Beachbody: Beachbody has developed and offering an in-home fitness and weight loss solutions.
Blake Mallen
Co-Founder & President of ViSalus
Blake Mallen is a Billion-Dollar Lifestyle Entrepreneur, CoFounder and President of two global lifestyle brands, TED Speaker, and Creator, who has spent over two decades helping people ‘wake up’ to become who they are ‘meant to’ be. After 19 years of excelling on the traditional path, yet never feeling fully fulfilled, Blake had a wake-up call: He had spent his entire life chasing achievements solely because it was what he was told he was “supposed to” do. Realizing that script would never lead to what he was really “meant to” do, Blake made the leap into entrepreneurship, becoming a self-made Millionaire by age 25 and co-owning a billion-dollar brand by his early 30s. Grateful for his journey, Blake gives back by empowering entrepreneurs and leaders to ‘shift the script’ so they too can find what they’re meant to do, become who they’re meant to be, and feel more alive. Blake builds companies that are aligned with his mission. He is a creator of products, programs, and platforms that have impacted over 3 million people and inspired mainstream movements expanding across 15+ countries. In his early 20s, Blake’s co-founded Vi, a health transformation platform that has generated more than $2 billion in cumulative revenue, was coined the “#1 Weight-Loss and Fitness Challenge in America,” has impacted millions, and is now expanding across Europe and Latin America. Blake also serves as the President of Vi’s sister company, Liv, an experience platform he co-founded to inspire people to trade in the notion of the “Bucket List” for a “Liv List,” by providing the everyday person access to extraordinary curated life experiences. Passionate about helping entrepreneurs create mission-driven movements, Blake takes on investor and advisor roles in select passion projects, and is a partner in HashTagOne, a $20M investment fund that invests in High Growth Seed and Series A companies. A values-driven leader, Blake is married to his high school sweetheart and has daily ‘dad-life’ adventures with his young son, daughter, and their big American Bulldog. From life enthusiast and high adventurer, to health advocate and longtime surfer, to world traveler and family man, Blake actively lives the lifestyle brands he sells. Blake is also a globally recognized influencer, thought leader, conscious living expert, and speaker, who is often profiled in industry publications (Forbes, Entrepreneur, Inc., SUCCESS) speaking on the topics of entrepreneurship, personal development and leadership. He has spoken in thousands of live events, to hundreds of thousands of people, and his recent TED Talk: “Shift The Script – Why Your ‘Supposed To’ No Longer Works,” is inspiring a movement to help even more “wake up,” move toward their “meant to,” and feel more ALIVE!
Follow Blake Mallen:
About Liv Global, ViSalus: ViSalus is a health promoting company that created the Body by Vi 90-Day Challenge.
Ade Adesanya
Co-founder & President of Moving Analytics
Follow Ade Adesanya:
About Moving Analytics: Moving Analytics is a provider of turnkey and home-based post-acute care management solutions for cardiopulmonary disease.
Surendar Magar
President and CEO of LifeSignals
Surendar Magar has over 30 years’ experience in the technology industry. He co-invented the Texas Instruments TMS320, the groundbreaking digital signal processing architecture that launched the DSP industry. Later he co-founded Athena Semiconductors, an early developer of the wireless networking platform that would become Wi-Fi; Athena was acquired by Broadcom Corporation.
Follow Surendar Magar:
About LifeSignals: LifeSignals’ offers innovation in wearable biosensor technologies to address a broad set of needs and opportunities throughout healthcare.
John Jellinek
Founder and President of Jelco Ventures
John Jellinek serves as the President of Jelco Ventures, Inc., a private equity investment firm he founded in 1971. During the last thirty years, John has had a hand in over fifty private equity transactions. Of all these transaction, some of the more notable ones include Bell Sports Corporation, IMNET Systems, Inc., Apogent Technologies, Tapscotts, Inc., Labor Source LLC, Pelstar LLC and CourtLink. Aside from running Jelco Ventures, Inc., John Jellinek was a shareholder and operating director of the boutique, mid-market investment bank BPC Group. He was also a director and founder of the following following companies, K2 Industrial, Inc., Pelstar LLC, and Capital Resources Advisors. From April 2005 to June 2011, John has been serving as the Chairman of Zenith Administrators Inc., a third party employee benefit plan administrator serving multi-employer, single employer and public employer benefit plans. In addition, John was the treasurer of the Aspen Valley Hospital Board of Trustees. John Jellinek attended Miami University where he obtained his Bachelor of Science degree, as well as the University of Chicago where he received his Master of Business Administration. At Miami University, John is the co-founder of the Entrepreneur Foundation and serves as co-trustee of the Miami University fund and Business School Board. Aside from John Jellinek’s business ventures, he is a part of numerous charities. He helped his wife in 2004 in founding the Aspen’s Writers’ Foundation. Currently, the Aspen’s Writers’ Foundation is one of the nation’s best literary centers and a platform for the world’s most established authors. John Jellinek is a major donor and advisor to the Aspen Community Foundation, American Diabetes Foundation, American Lupus Foundation, Sharp Community Hospital of San Diego, and is also a major donor to the Museum of Contemporary Art in La Jolla.
Follow John Jellinek:
About Jelco Ventures: Jelco Ventures has been active in the acquisition and management of business entities primarily in healthcare, IT, and infrastructure.
Robert J. Beck
President of US Operations of Medusind Solutions
Robert, fondly called Bob, heads our US offices and is responsible for all sales, marketing and operations. Prior to joining Medusind, he spent more than 25 years in the healthcare field holding senior management positions in a number of healthcare companies. As Founder and President of Hamilton Computer, he brought that company to prominence in providing software to the dental profession. He also served as Executive VP of Quality Systems Inc. a publicly held leading provider of medical and dental practice management systems. In a consulting role, he assisted Discus Dental in bringing its consumable and software products to the dental group marketplace and Software of Excellence, a New Zealand publicly traded company where he successfully brought their healthcare software products to the commercial, university and public health markets. During his time with these companies he participated in four acquisitions allowing the respective companies to build a base for future growth. He also served as President of Volt Computer Services and Executive Vice President of Sandata, Inc. Bob has a degree in Mathematics & Statistics from Hunter College, New York.
Follow Robert J. Beck:
About Medusind Solutions: Medusind Solutions®, one of the leading outsourcing companies, provides integrated healthcare business solutions, both on and offshore.
Hartmuth Kolb
Vice President, Neuroscience Biomarkers and Janssen R&D Global Imaging of Johnson & Johnson
Follow Hartmuth Kolb:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Andrew Toy
CTO & President of Clover Health
Andrew is currently the Chief Technology Officer of Clover Health, a technology oriented Medicare Advantage company focused on changing healthcare by developing models and interventions that improve member outcomes. Prior to Clover, Andrew was a Product Management Director at Google working in the Google Cloud team and was responsible for Developer Platform and Intelligence features. Previously, he was the Product Director for Android for Work – the enterprise platform for Android. Andrew joined Google in 2014 via the acquisition of Divide where he was co-founder and CEO. At Divide, Andrew helped drive the company’s founding vision of bringing Work and Play together on a single device with no compromises. Divide raised over 25MM in venture funding before being acquired by Google. Before co-founding Divide in 2010, Andrew was VP of Mobile and Syndication Technology at MTV Networks. In this role, he provided technological leadership for digital distribution of Viacom content, serving cable brands including MTV, VH1, Comedy Central, and Nickelodeon. Prior to joining MTV Networks, Andrew headed mobile application development for Morgan Stanley, where he specialized in mobile security as well as fixed-mobile convergence telephony. Before Morgan Stanley, Andrew was chief architect for Jarna Inc., a startup focused on enabling mobile workflows on event-based platforms. Andrew holds both a B.S. and M.S. in Computer Science from Stanford University, where he has also served as an associate lecturer.
Follow Andrew Toy:
About Clover Health, Divide: Clover is a healthcare technology company helping members live their healthiest lives with its Medicare Advantage plans.
Anatoly Tikhman
Co-Founder, President, & CEO of Monclarity
Anatoly Tikhman joined Monclarity as Co-Founder, President, & CEO in 2012.Anatoly has more than 20 years of high-tech industry experience developing and marketing innovative software applications. He is a successful entrepreneur, computer scientist and technology visionary. Anatoly’s ability to forge strategic technology license agreements with companies such as Microsoft has resulted in tens of millions of PCs carrying the technology he developed as a part of Microsoft Windows. Anatoly founded a number of companies, most of which were acquired by public companies such as Microsoft, Quarterdeck, Symantec, L&H, VASCO Data Security and others. Anatoly created cutting-edge, best-selling applications for technologies such as lossless data compression, speech recognition, biometrics, and several others. He is currently the Chairman of TikGames, LLC, which he founded in 2002. He built an industry-leading studio that has delivered a broad range of top quality proprietary and licensed games for numerous platforms. Among some of the highlights are Texas Hold’em Poker for Microsoft Xbox which is one of the most successful games in XBLA’s run, as well as the megahit Cuboid for Sony PlayStation.
Follow Anatoly Tikhman:
About Monclarity, Playteau, TikGames: Monclarity has assembled a unique interdisciplinary team of scientists and professionals.
Ben Hindson
CSO, CO-Founder & President of 10X Genomics
Ben Hindson has served as Chief Scientific Officer and Director of 10x Genomics since its founding in 2012. Prior to 10x Genomics, Hindson was Co-founder and Chief Scientific Officer of Quantalife, a privately-held life sciences company that developed and commercialized a droplet digital PCR platform, until its sale to Bio-Rad in 2011. From 2002 to 2008, he served in various positions of increasing responsibility at Lawrence Livermore National Laboratory, in the Chemical and Biological Weapons Non-proliferation Program. He has published extensively in his field and holds many patents for assays and instrumentation. Hindson earned his BSc in Chemistry in 1998 and his PhD in Chemistry in 2001 from Deakin University, Australia.
Follow Ben Hindson:
About 10X Genomics: 10X Genomics ELV solutions and security systems company that provides an innovative genomics platform.
Asish Xavier
Vice President, Venture Investments of Johnson & Johnson Development Corporation
Asish Xavier is the Vice President of Venture Investments at joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 2004. Asish is based in Silicon Valley, California. Asish previously worked in business development at BioRexis Pharmaceutical, Inc., which was acquired by Pfizer in 2007. While at BioRexis, Asish assisted the company in raising a $30 million second round of financing. Asish has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc. Asish received a Ph.D. from the University of Houston and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he graduated with honors. Asish received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. Asish was also a postdoctoral research Fellow in the Department of Chemistry at Johns Hopkins University.
Follow Asish Xavier:
About Cue, ESCAPE Bio, Johnson & Johnson Development Corporation, Legend Biotech, Paige, ViaCyte, XWPharma: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Stacy Feld
Vice President, Consumer Venture Investments of Johnson & Johnson Development Corporation
Stacy received a B.A. in sociology, graduating magna cum laude from the University of Pennsylvania and earned her J.D. from Vanderbilt Law School.
Follow Stacy Feld:
About Johnson & Johnson Development Corporation, Johnson & Johnson Development Corporation: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Albert Chan
Enterprise Vice President, Chief of Digital Patient Experience of Sutter Health
Albert Chan, M.D., M.S., FAAFP, as Vice President, Chief of Digital Patient Experience at Sutter Health, is the corporate champion for the transformation of web and mobile health care services, translating the latest advancements in digital health into consumer-centric patient experiences and digitally empowered clinician workflows. He also leads the Sutter Health My Health Online initiative. He practices in Family Medicine at the Palo Alto Medical Foundation. He earned a bachelor’s degree with honors in Biological Sciences from Stanford University and a medical degree from the University of California, San Diego School of Medicine. He completed his residency and year as chief resident in family medicine at the San Jose Medical Center Family Practice Residency, affiliated with Stanford University of School of Medicine. He concurrently completed a postdoctoral fellowship in Biomedical Informatics at Stanford University School of Medicine and Family Medicine Research at the University of California, San Francisco School of Medicine, studying the effects of point of care decision support in the management of hypertension. During fellowship, Dr. Chan also assisted with the launch of PAMFOnline, now Sutter’s My Health Online, one of the earliest PHRs in the United States.
Follow Albert Chan:
About Sutter Health: Sutter Health is a non-profit organization operating a network of hospitals and physicians in Northern California.
Patrick E. Fry
President of Sutter Health
Mr. Patrick E. Fry, also known as Pat, serves as the President of Sutter Health. Mr. Fry served as Chief Executive Officer of Sutter Health until December 2012. He served as Administrative Resident of Sutter General Hospital in Sacramento since joining in 1982. From 2000 to 2005, he was Sutter Health’s second-in-command, served as its Chief Operating Officer and Executive Vice President. Over the ensuing years, Mr. Fry worked his way up through Sutter Health in increasingly responsible administrative positions both at the local affiliate and regional levels. In 1996, after serving as Regional President for Sutter Health’s affiliates in the Greater Sacramento Region, Mrhe served as the President of eastern operations, which covered 18 counties in the Sacramento and San Joaquin Valleys. In 1999, Mr. Fry relocated his office to San Francisco, assuming leadership of Sutter Health’s Western Division, which included more than a dozen hospitals and physician organizations throughout the Greater Bay Area. Mr. Fry has been Chairman of the Board of VHA, Inc. since May 17, 2011 and as its Director since May 28, 2009. He serves as a Director of Sutter West Bay Hospitals, Sutter Amador Hospital, and Sutter Health. He served as Director of Novation, LLC. He served as a Director of St. Luke’s Hospital and California Pacific Medical Center. He serves as a Member of the American College of Healthcare Executives and Medical Group Management Association. Mr. Fry graduated from the University of California, Davis in 1979 with a Bachelor’s degree in Public Health Administration, and received a Master’s Degree in Health Services Administration from George Washington University in Washington, D.C. in 1982.
Follow Patrick E. Fry:
About Sutter Health: Sutter Health is a non-profit organization operating a network of hospitals and physicians in Northern California.
Gerald McMahon
President & CEO of Harpoon Therapeutics
Dr. McMahon joined Harpoon in December 2016 bringing more than 25 years of biotechnology leadership, scientific innovation and creative deal-making experience. Dr. McMahon was previously president and CEO of Kolltan Pharmaceuticals, an oncology biologics company acquired by Celldex in 2016, and senior vice president of R&D oncology at MedImmune, the biologics arm of AstraZeneca. He also served as a venture partner at Bay City Capital and in executive leadership roles at Poniard Pharmaceuticals and SUGEN (ultimately acquired by Pfizer), where he was a key player in the development of innovative oncology drugs Sutent® and Palladia®. Dr. McMahon holds an academic appointment at the Yale Comprehensive Cancer Center at Yale University, and held previous appointments at Tufts University School of Medicine, department of hematology & oncology at the New England Medical Center, and the Massachusetts Institute of Technology. He received his BS in biology and PhD in biochemistry from Rensselaer Polytechnic Institute.
Follow Gerald McMahon:
About Harpoon Therapeutics: Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Hakan Sakul
Vice President and Head of Diagnostics of Pfizer
Follow Hakan Sakul:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Dave Scheinman
President of SummerBio
Dave Scheinman is the President at SummerBio.
Follow Dave Scheinman:
About SummerBio: Lab Diagnostics
Bob Colloton
Vice President of Sales & Marketing of Neuravi
Follow Bob Colloton:
About MIVI Neuroscience, Neuravi: Neuravi provides medical products and services.
Joshua Sommerfeld
Vice President of Redmile Group
Josh is a member of the investment team at Redmile Group. Prior to Redmile, Josh was Director of Operations at Stride Health, where he built the company’s sales, customer support, regulatory, and data operations teams. Prior to Stride Health, Josh was the lead Associate for Bain Capital Venture’s early-stage and growth equity activity in the healthcare vertical, where he focused on healthcare IT and healthcare services. Companies in Josh’s portfolio included Liazon (sold to Tower’s Watson) and National Cardiovascular Partners (sold to Fresenius). Josh began his career as a management consultant at Bain & Company in Chicago and Melbourne, Australia. Josh graduated with honors from University of Chicago where he received a BA in South Asian Languages and Civilizations.
Follow Joshua Sommerfeld:
About Redmile Group, Wellington Management: Redmile Group is a healthcare investment organization that makes venture, growth, and crossover investing across healthcare.
Steve Pham
Vice President of Clinical and Research Affairs of Eko Health
Steve Pham is a practicing emergency medicine physician, the head of medical and research affairs at Eko, and a new father. His passion is translating between digital and clinical insights.
Follow Steve Pham:
About Eko Health: Eko develops AI-powered digital tools to detect and monitor heart and lung disease
Gene Hung
Co-founder and Senior Vice President of XinThera
Gene Hung is a Co-founder and Senior Vice President at Xinthera Inc.
Follow Gene Hung:
About XinThera: XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Pat Patnode
President of Licensing of GE Ventures
Patrick Patnode is the President of Licensing at GE Ventures.
Follow Pat Patnode:
About GE Ventures: GE Ventures combines capital, expertise, infrastructure, and the GE global network to help accelerate the growth of businesses.
Kathryn E. Falberg
Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals
Kathryn Falberg was appointed our Executive Vice President and Chief Financial Officer in March 2012. She served as our Senior Vice President and Chief Financial Officer from 2009 to 2012. Her responsibilities include finance, strategy, corporate development and IT. From 1995 through 2001, Kathryn Falberg was with Amgen, Inc., where she served as Senior Vice President Finance, Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. From 2001 through 2008, Kathryn Falberg was President of Canyon Capital & Consulting, a private investment and consulting firm, where she worked with a number of smaller companies while also serving as a corporate director and audit committee chair for several companies. From February to November 2009, she was Chief Financial Officer and Chief Operating Officer at ARCA biopharma, Inc., a biopharmaceutical company. Kathryn Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant (inactive). Kathryn Falberg currently serves on the boards, and is chair of the audit committees, of biopharmaceutical companies Halozyme Therapeutics, Inc. and Medivation, Inc.
Follow Kathryn E. Falberg:
About Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.
Robert Desantis
Executive Vice President Chief Product Officer of Intuitive Surgical
Bob DeSantis joined Intuitive Surgical in January 2013 as Vice President, Research and Development, Instruments and Accessories Engineering. In November 2015, Mr. DeSantis was promoted to the position of Senior Vice President, Instruments and Accessories. In this position, Mr. DeSantis is responsible for managing the development of new technology from design to market as well as production engineering support for the instrument and accessory portfolio. Prior to joining Intuitive Surgical, Mr. DeSantis spent almost twenty years in the medical device industry, holding positions at several companies, including US Surgical and most recently at Covidien, where he last served as the Vice President, Research and Development for the mechanical and energy instrument businesses. Mr. DeSantis holds a B.S. and M.S.in Mechanical Engineering from the State University of New York at Buffalo. Mr. DeSantis also holds a certificate in Innovation Management from MIT.
Follow Robert Desantis:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
Dave Rosa
Executive Vice President & Chief Business Officer of Intuitive Surgical
Dave J. Rosa joined Intuitive Surgical in March 1996 and has held leadership positions in Engineering, Clinical Development, Marketing and Product Development. In 2015, Mr. Rosa was appointed as Executive Vice President and Chief Commercial Officer. In 2013, Mr. Rosa assumed the position of Senior Vice President, Scientific Affairs and, in 2014, he was appointed as Executive Vice President and Chief Scientific Officer. He has been a passionate supporter and evangelist of da Vinci technology since its inception. Prior to joining Intuitive Surgical, Mr. Rosa contributed to the development of trans-esophageal transducers for Acuson Corporation. He graduated magna cum laude with a B.S.in Mechanical Engineering from California Polytechnic University at San Luis Obispo. He also holds a M.S. in Mechanical Engineering from Stanford University.
Follow Dave Rosa:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
Gillian Duncan
Senior Vice President, Professional Education & Program Services – Worldwide of Intuitive Surgical
Gillian Duncan, Ed.D., joined Intuitive Surgical in December 2006 as an Education Manager. After holding several positions of increasing responsibility in clinical, product and professional education, Dr. Duncan was promoted to the position of Vice President, da Vinci® Professional Education & Program Services – Worldwide in August 2015. In this role, Dr. Duncan is responsible for leading the company’s high-quality, worldwide Customer Training, Genesis, Lab Services and Clinical and Product Education programs. Prior to joining Intuitive Surgical, Dr. Duncan held both teaching and research positions at Columbia University and California State University, East Bay. Dr. Duncan holds a B.A. in Rhetoric from the University of California, Berkeley, and master’s and doctorate degrees in Applied Physiology from Columbia University.
Follow Gillian Duncan:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
Myriam Curet
Executive Vice President & Chief Medical Officer of Intuitive Surgical
Myriam J. Curet, M.D. joined Intuitive Surgical in December 2005, as Chief Medical Advisor. In February 2014, Dr. Curet was promoted to the position of Chief Medical Officer. Dr. Curet also held a faculty position as Professor of Surgery at Stanford University. Since October 2010, she has served as a Consulting Professor of Surgery at Stanford University with a part time clinical appointment at the Palo Alto Veteran’s Administration Medical Center. Dr. Curet received her M.D. from Harvard Medical School and completed her general surgery residency program at the University of Chicago. She then worked for the Indian Health Service for four years before finishing her Surgical Endoscopy fellowship at the University of New Mexico. She was on the faculty at the University of New Mexico for six years prior to joining the Stanford University Department of Surgery in 2000.
Follow Myriam Curet:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
Craig Child
Sr. Vice President, Human Resources of Intuitive Surgical
Craig Child joined Intuitive Surgical in May 2001 as a Recruiting Consultant. In March 2015, Craig Child was promoted to the position of Vice President, Human Resources. Prior to this role, Mr. Child has held several key positions since the inception of the human resources organization at Intuitive Surgical, playing an instrumental role in the development of key human resources functions. Prior to joining Intuitive Surgical, Mr. Child held positions in human resources at Adobe and Informix. Mr. Child holds a B.A. in Psychology from the University of Oregon and a M.B.A from Colorado State University.
Follow Craig Child:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
Charles Jones
Senior Vice President, Design and User Experience of Intuitive Surgical
Charles Jones joined Intuitive Surgical in April 2016 as the Senior Vice President, Design and User Experience. In this role, Mr. Jones is responsible for leading the company’s efforts to blend leading-edge technology with enhanced human-centered design thinking and driving a consistent design experience for Intuitive products and services. Prior to joining Intuitive Surgical, Mr. Jones has held several key leadership roles at Whirlpool Corp., Xerox Corp. and Herman Miller, and most recently served as the Chief Design and Technology Officer for Newell Rubbermaid. Mr. Jones has received several international design awards, including the prestigious Smithsonian National Design Award, and holds several patents. Mr. Jones is an honors graduate from Purdue University with degrees in Industrial Design and Human Factors Engineering.
Follow Charles Jones:
About Intuitive Surgical: The da Vinci Surgical System is changing the experience of surgery for patients around the world.
Carla Brenner
President and Founder of Healthtech Women
Follow Carla Brenner:
About Healthtech Women: Healthtech Women is global non-profit organization that supports women shaping and impacting health technologies.
James Hinrichs
Executive Vice President and Chief Financial Officer of Alere
James (“Jim”) Hinrichs joined Alere in April 2015 as Executive Vice President and Chief Financial Officer, with global responsibility for Finance, Accounting, Procurement, IT and Shared Services. Prior to his appointment as CFO of Alere, Jim Hinrichs was CFO at CareFusion Corp., a global medical technology corporation, since 2010. He held this position through the completion of Becton Dickinson’s acquisition of CareFusion in March 2015. Prior to this role, Hinrichs served as SVP of Global Customer Support and, before that, Corporate Controller of CareFusion. Previously, he was Executive Vice president and Controller of Cardinal Health, CFO of Cardinal Health’s Clinical and Medical Products segment and CFO of Cardinal Health’s Healthcare Supply Chain Services segment.. He joined Cardinal Health in February 2004, following 12 years of finance and marketing roles at Merck & Co. and two years as the CFO of SangStat Medical Corporation.
Follow James Hinrichs:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Mark Gladwell
Senior Vice President, Global Operations of Alere
Mark Gladwell has served as Senior Vice President, Global Operations since January 2015. From January 2014 through January 2015, he held the role of Vice President, Operations for North America, Europe, Middle East and Africa. From September 2011 through December 2013, Mr. Gladwell served as Vice President of Operations for North America and as President and General Manager of one of Alere’s key manufacturing facilities in North America. From 2007 to 2010 Mr. Gladwell was Vice President, Quality and Technical Service for Alere. From 2005 to 2007, he served as a director covering multiple functions in the start-up of Alere Technology Limited where he focused on the development and manufacture of the Alere home BNP product. Prior to 2005 Mr. Gladwell held a variety of operations, quality and project leadership positions in North America and Europe for Alere, Johnson & Johnson, Agfa Gavert and DuPont. Mr. Gladwell has more than 18 years of experience in manufacturing high-volume, high-technology in-vitro diagnostics and medical devices.
Follow Mark Gladwell:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Christopher Anzalone
President & CEO of Arrowhead Pharmaceuticals
President & CEO at Arrowhead Research.Dr. Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007. In 2005, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring, and building new business ventures. Prior to Galway, Dr. Anzalone was an NIH-supported post doctoral fellow in Reproductive Endocrinology at the Smithsonian Institution’s Conservation and Research Center. Dr. Anzalone holds a Ph.D. in Biology from UCLA and a B.A. in Government from Lawrence University.
Follow Christopher Anzalone:
About Arrowhead Pharmaceuticals, Galway Partners: Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Gerrit Klaerner
Chief Executive Officer & President of Tricida
Gerrit joined Relypsa in October 2007 after negotiating the Relypsa spin out transaction from Amgen as an advisor to the lead investor 5AM Ventures. He co-founded Ilypsa in 2003 while at Symyx Technologies. Between 2003 and 2007, Gerrit held varying positions at Ilypsa and was in charge of the series A and B financings on the company side and licensing deals with Astellas and Cubist. As Ilypsa’s Chief Business Officer, Gerrit co-led the M&A negotiations and diligence efforts. Prior to Ilypsa, he joined Symyx in 1998 as a Staff Scientist, and was later promoted to Director of Business Development. Gerrit received his Ph.D. in polymer chemistry from the Max-Planck-Institute for Polymer Research in Mainz, Germany. He conducted postdoctoral research at Stanford University and the IBM Almaden Research Center.
Follow Gerrit Klaerner:
About Tricida: Tricida operates in the healthcare industry focusing on pharmaceutical business.
Mark McCamish
President and Chief Executive Officer of Forty Seven
Dr. McCamish is President and Chief Executive Officer of IconOVir Bio. Previously he was President and Chief Executive Officer of Forty Seven, Inc. He led Forty Seven, Inc. during critical phases of clinical development to help patients defeat their cancer. This included growing from a valuation of $169 million as a private company through a Series B offering, Initial Public Offering, two secondary fund raises and finally the acquisition of Forty Seven by Gilead for $4.9 Billion. He is an international expert in biologic and biosimilars development and manufacturing. Mark is passionate about mentoring and developing people while focusing on meeting patient needs through efficient, commercially viable efforts. He is a senior executive with extensive experience at multiple companies including Abbott, Amgen, and Novartis/Sandoz. He led pioneering efforts in filing/launching biosimilars worldwide. He has demonstrated a commercial mindset in establishing research and development strategies leading to approvals and commercial success in multiple therapeutic areas and regulatory categories including biologics, biosimilars, drugs, devices, and medical foods. He received Bachelor’s and Master’s degrees from UCSB and, after completing his PhD in Human Nutrition from Penn State and MD from UCLA, he completed Residency and Fellowship Training at the University of California, Davis. He held professorships at UC Davis and The Ohio State University
Follow Mark McCamish:
About Forty Seven, IconOVir Bio, Nemesis Bioscience: Forty Seven is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways.
Charles Yang
Vice President of Quality Assurance & Regulatory Affairs of Blockade Medical
Charles is currently the Vice President of Quality Assurance and Regulatory Affairs at Blockade Medical. He has been in the medical device industry for over 15 years in the quality and regulatory field with extensive experience in achieving product approvals in a timely manner. Charles has been successful in achieving multiple product approvals through CE Mark, 510K and other regulatory processes all over the world. He has a diversified portfolio of working in start-up companies and large corporations which has allowed him to gain the experience to build efficient quality systems that meet the needs of the medical device industry. Prior to joining Blockade Medical, Charles worked at various medical device companies which include Acutus Medical, MindFrame Inc. (acquired by Covidien), Ablation Frontiers (acquired by Medtronic) and Edwards LifeSciences. Charles received a B.S. in Bio-engineering at the University of California, San Diego.
Follow Charles Yang:
About Blockade Medical: Founded in 2011, Blockade Medical is a privately held company dedicated the development of catheter based therapeutic devices for the
Ryan Solomon
Vice President of Marketing & Business Development of Blockade Medical
Ryan is the Director of Global Marketing and Business Development at Blockade Medical and has more than 10 years of medical sales and marketing expertise including extensive interventional neurovascular experience. Ryan has successfully launched many products in the neurovascular field including launching the first flow diversion device in the United States while serving as the Group Marketing Manager at Covidien Neurovascular and global launches of multiple coil lines as a Sr. Product Manager at MicroVention. His previous roles have also included Associate Marketing Manager at Karl Storz Endoscopy, Sr. Clinical Sales Specialist at Glaxo Smith Kline, and a Professional Sales Representative for Boehringer Ingelheim. Ryan received a B.S. in Business Administration from the University of California, Riverside and a M.B.A. from the University of California, Irvine.
Follow Ryan Solomon:
About Blockade Medical: Founded in 2011, Blockade Medical is a privately held company dedicated the development of catheter based therapeutic devices for the
Jeffrey Brewer
President & CEO of Bigfoot Biomedical
Follow Jeffrey Brewer:
About Bigfoot Biomedical: Bigfoot Biomedical is a medical device company changing diabetes care for people with insulin-requiring diabetes.
Thomas W. Burns
President & Chief Executive Officer of Glaukos
Thomas W. Burns has served as our president, chief executive officer and as a member of our board of directors since March 2002. Mr. Burns has also been a member of the board of directors of DOSE Medical Corporation since October 2009 and its chief executive officer and president since March 2010. Mr. Burns has a proven record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns has more than 25 years of direct ophthalmic management experience, including over 20 years of general management experience across a broad range of ophthalmic medical devices, ophthalmic pharmaceuticals, drug delivery technologies, surgical products and over-the counter products. Prior to joining our company, Mr. Burns led Eyetech Pharmaceuticals, Inc. (acquired by OSI Pharmaceuticals, Inc.) as its president and chief operating officer, and a director. From 1990 to 1997, Mr. Burns served as senior vice president and general manager of Chiron Vision Corporation (acquired by Bausch & Lomb, Inc.), and then as vice president, global strategy and general manager, refractive surgery of Bausch & Lomb from 1998 to 2000. Mr. Burns has also served as an entrepreneur-in residence at Versant Ventures Management, LLC, an entity affiliated with one of our principal stockholders. Mr. Burns received a B.A. from Yale University. We believe Mr. Burns’ extensive understanding of our business, operations and strategy, as well as significant industry experience and corporate management skills and experience qualify him to serve onour board of directors.
Follow Thomas W. Burns:
About Glaukos: Glaukos is a glaucoma treatment company developing micro-bypass therapies to moderate the intraocular pressures that help preserve vision.
Zachary Hornby
Chief Executive Officer & President of Boundless Bio
Zachary Hornby brings a dozen years of life sciences business experience to Ignyta. Prior to joining Ignyta, Mr. Hornby was senior director of business development at Fate Therapeutics where he was responsible for pharmaceutical partnerships and non-dilutive funding. Mr. Hornby has also served in various business and commercial roles at Halozyme Therapeutics (NASDAQ: HALO), Neurocrine Biosciences (NASDAQ: NBIX) and TKT (now Shire Human Genetic Therapies), and was a life sciences consultant at L.E.K. Consulting. Mr. Hornby holds B.S. and M.S. degrees in biology from Stanford University and an M.B.A. from Harvard Business School.
Follow Zachary Hornby:
About Boundless Bio, City Hill Ventures: Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Sherwin Sheik
Co-Founder, President & Chief Executive Officer of CareLinx
Sherwin Sheik is the Founder and CEO of CareLinx. CareLinx is a trusted nationwide home care platform with over 300,000 professional caregivers that help improve health outcomes while reducing cost of care. Our innovative approach amplifies the effectiveness of clinical teams by using tech-enabled caregivers who serve as their eyes, ears, and arms in the homes of patients and members. CareLinx was Acquired by Generali Global Assistance in Sep 2017. Generali is the 3rd largest insurance company in the world with global operations generating over $80b in annual revenue. CareLinx is continuing to operate under its own established brand with Sherwin Sheik continuing to lead the company as CEO. Prior to founding CareLinx, Sherwin worked and invested in the healthcare industry for over ten years. His business interests centered on large healthcare corporations while working as a healthcare trader and analyst for a $900 million Equity Long/Short Hedge Fund, and in Investment Banking & Global Capital Markets.
Follow Sherwin Sheik:
About CareLinx: CareLinx is a nationwide tech-enabled caregiver marketplace.
Billoo Rataul
President & CEO of Paramit Corporation
Billoo Rataul is the President & CEO at Paramit Corporation.
Follow Billoo Rataul:
About Paramit Corporation: Paramit designs and manufactures medical devices and life science instruments.
Bhavin Shah
Vice President of Engineering and Quality of Paramit Corporation
Bhavin joined Paramit in 2014. Bhavin brings with him over 20 years of experience in developing products involving hardware and software/firmware for multiple industries. Prior to Paramit, Bhavin spent 5 years at Diamond Systems, managing engineering teams developing high precision digital and analog PCBAs and 9+ years with Asyst Technologies. Bhavin has a BSEE from the Mumbai University(India) and a Post Graduate Diploma in Advanced Computing from C-DAC (India).
Follow Bhavin Shah:
About Paramit Corporation: Paramit designs and manufactures medical devices and life science instruments.
Francesco Grieco
Vice President of Operations of Paramit Corporation
Francesco Grieco is the VP of Operations at Paramit Corporation.
Follow Francesco Grieco:
About Paramit Corporation: Paramit designs and manufactures medical devices and life science instruments.
Sol Chen
Co-founder, President of Clara Health
Sol is the co-founder of Clara Health, a patient driven digital health company accelerating medical research by streamlining the process of participating in a clinical trial. By removing the two most common causes for clinical research delays, patient recruitment and retention, Clara Health has accelerated study timelines by over 400% for past clients, and is backed by Founders Fund, Khosla Ventures, and top angel investors. Sol left Brown University where she was studying computer science, mathematics, and economics during her junior year to found Clara Health. She received the Forbes 30 Under 30 award and Thiel Fellowship created by Peter Thiel, the founder of PayPal. Before founding Clara Health, Sol previously conducted research in theoretical mathematics at Boston College, computational genomics at the University of Michigan, and computer vision at MIT. She is also a Venture Partner at Alix Ventures, and is particularly excited about startups focused on making increasing access to healthcare, preventative healthcare, AI/ML, and marketplace companies.
Follow Sol Chen:
About Clara Health: Clara Health empowers patients to find the right clinical trial for them.
Ed Chuang
Vice President, Marketing and Business Development of ClearCare
Follow Ed Chuang:
About ClearCare: ClearCare is a web-based software solution that helps home care agencies efficiently focus on what’s important: providing better care.
Thomas Alessi
Vice President, Development and Manufacturing of Intarcia Therapeutics
Dr. Alessi joined Intarcia in December 1997 as Executive Director, Regulatory Affairs and Drug Development and was promoted to Vice President, Development in February 2002 with responsibility for the areas of product development, project management, chemistry and manufacturing. Prior to joining Intarcia, Dr. Alessi served as the Senior Director, Regulatory Affairs, Quality Assurance and Project Management at Ansan Pharmaceuticals where he was responsible for successful IND filings and for managing five drug development programs with oversight of vendors for preclinical and clinical studies and manufacturing clinical supplies. Before joining Ansan, Dr. Alessi was Director of Regulatory Affairs and Quality Assurance at Glycomed, Inc. where his duties included oversight and compliance of clinical manufacturing. His previous experience includes regulatory affairs and drug discovery experience in large pharmaceutical companies. Dr. Alessi was Senior Manager of Regulatory Affairs for Schering-Plough working in the Anti-infectives, Allergy Products and Chemisty, Manufacturing, & Controls groups. While at Schering-Plough, Dr. Alessi had regulatory responsibilities for approval and launch of interferon alfa-2b for hepatitis C as well as for hepatitis B. In his CMC role, he served on separate committees for process development and production of solid oral dosage forms, inhaled products, creams and semisolid products and sterile dosage forms, in addition to regulatory review of the CMC sections of Schering-Plough INDs and NDAs. Prior to joining Schering-Plough, Dr. Alessi invented and patented several new families of antidiabetic drugs while working as a Senior Scientist in the drug discovery group at Wyeth-Ayerst. Dr. Alessi earned a B.S. degree at Allegheny College and an M.S. and a Ph.D. in organic synthetic chemistry from the University of Rochester.
Follow Thomas Alessi:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Athena Countouriotis
President and Chief Executive Officer of Turning Point Therapeutics
Athena Countouriotis became president and chief executive officer and was named to the Turning Point Therapeutics board of directors in September 2018. She has broad oncology biotech leadership experience, guiding multiple development programs to approval. Her experience includes large and small molecule therapeutics in hematologic and solid tumor indications, with multiple regulatory approvals in the U.S. and Europe. She joined Turning Point Therapeutics in May 2018 as executive vice president and chief medical officer to advance the clinical development of repotrectinib. She previously served as senior vice president and chief medical officer for Adverum Biotechnologies, and before that as senior vice president and chief medical officer of Halozyme Therapeutics. Athena Countouriotis also served as chief medical officer of Ambit Biosciences, where she helped lead the company’s initial public offering and was responsible for the clinical development of quizartinib until the company’s acquisition by Daiichi Sankyo in November 2014. Earlier in her career, Athena Countouriotis led various clinical development organizations within Pfizer and Bristol-Myers Squibb for oncology therapeutics including Sutent®, Mylotarg™, Bosulif® and Sprycel®. Athena Countouriotis also serves on the board of directors of Trovagene and NuMedii. She earned a Bachelor of Science degree from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial medical training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program.
Follow Athena Countouriotis:
About Turning Point Therapeutics: Turning Point Therapeutics is a structure-based drug design pharmaceutical company.
Paul Negulescu
Vice President of Vertex Pharmaceuticals
Paul Negulescu is the Senior Vice President and Site Head of San Diego Research. He’s been leading Vertex’s San Diego research location since 2003, the site that discovered Vertex’s medicines that treat the underlying cause of cystic fibrosis. Prior to joining Vertex, Dr. Negulescu was Senior Vice President of Discovery Biology and a member of the executive team at Aurora Biosciences. When Vertex acquired Aurora, he was responsible for integrating Aurora’s research into Vertex. Dr. Negulescu received both his B.S. and Ph.D. from U.C. Berkeley in Physiology and carried out post-doctoral work at U.C. Berkeley and U.C. Irvine in the areas of ion channel biophysics and immunology.
Follow Paul Negulescu:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Glenn S. Boehnlein
Chief Financial Officer & Vice President of Stryker
Follow Glenn S. Boehnlein:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Shian-Jiun Shih
Vice President of Product Development of Tessa Therapeutics
Dr. Shih has over 20 years of experience in the biopharmaceutical industry, with strong expertise in biological drug development, including cell and gene therapy products and therapeutic proteins, with a focus on immunotherapy. Prior to joining Tessa, she was Director of Molecular Biomarkers and Site Lead of the Translational Medicine and Research Centre, Merck Sharp & Dohme. In that role, her group established non-human primate disease models and developed clinical biomarker assays to support early phase clinical trials, including those for Keytruda. Before that she was Director, Assay Development, Cell Genesys, Inc. She has also held various roles in Bayer, Aventis, and Applied Immune Sciences. Dr. Shih is Founding President of the Chinese Bioscience Association. She holds a Ph.D. in Biochemistry from University of Wisconsin at Madison and completed her post-doctoral training at the School of Medicine, Stanford University.
Follow Shian-Jiun Shih:
About Tessa Therapeutics: Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors.
Darren Hudgins
Vice President, Software Engineering of Breathometer
Darren Hudgins is the Vice President, Research & Development of Hillrom.
Follow Darren Hudgins:
About Breathometer, Hill-Rom: Breathometer develops a breath analysis technology that helps people make smarter decisions and improve their lives.
Padmasree Warrior
Founder, President, & CEO of Fable
Padmasree Warrior is the Founder, President, and Chief Executive Officer at Fable. She is also the Chief Executive Officer of NextEV, U.S. She also serves as the Chief Development Officer of NextEV, as well as a member of its Board of Directors. In these capacities, she is responsible for the brains of NextEV’s autonomous, electric vehicles and the overall user experience. She is based in San Jose, CA where NextEV US is headquartered. Previously, Warrior served as the Chief Technology & Strategy Officer (CTSO) for Cisco until September 2015. In this capacity she was charged with aligning the company’s technology and business strategy to business results. She was in charge of corporate strategy, mergers, acquisitions, venture investments, and strategic partnerships. Previous to that she was the GM for Cisco Enterprise segment and co-led Cisco’s worldwide engineering organization. Prior to joining Cisco, she was executive vice president and CTO at Motorola. Under her leadership, Motorola was awarded the 2004 U.S. National Medal of Technology. Padmasree Warrior has been widely recognized for her creative, visionary leadership. Forbes has named her one of “The World’s 100 Most Powerful Women” for three years running. In 2013, The International Alliance for Women gave her the World of Difference Award. In 2012, Business Insider called her one of the “25 Most Influential Women in Wireless”. The Aspen Institute gave her the first Leadership in Science and Technology Award. India’s National Association of Software & Service Companies (NASSCOM) named her the Global CTO Award winner. The Wall Street Journal has called her one of “50 Women to Watch.” Fast Company included her among the “100 Most Creative People in Business.” The Economic Times listed her as “the 11th Most Influential Global Indian.” Warrior holds a Bachelor of Science degree in Chemical Engineering from the Indian Institute of Technology in New Delhi and a Master of Science degree in Chemical Engineering from Cornell University. In addition to NextEV’s board, Warrior serves on the board of Microsoft. She previously served on the board of Gap and Box.
Follow Padmasree Warrior:
About Fable: Fable provides a platform for online book clubs.
Zach Phillips
Co-Founder & President of Nom Nom
Zach is Nom Nom’s co-founder and President, overseeing operations, growth and customer experience. Prior to Nom Nom, Zach served as the GM of Games at Upsight, a leading mobile-first analytics and advertising platform during the height of the mobile gaming rush. Zach received his BA from Occidental College in Los Angeles.
Follow Zach Phillips:
About Nom Nom: We make real food to support healthier, longer lives for folks with paws. Because what’s good for people is good for pets too.
Heather A. Brown
Senior Vice President, Market Access & Reimbursement of HeartFlow
Dr. Brown brings 10 years of experience in advanced medical imaging product development and service. She has held leadership roles in multiple startups and drove the development of AAA stent graft and TAVR planning applications as well as novel methods of assessing cardiac wall mechanics. Dr. Brown developed the first Volumetric Medical Imaging college accredited program at Jefferson Community and Technical College in 2005. She holds six patents. She received her B.S. degree in Mechanical Engineering from Michigan Technological University, and M.S. and Ph.D. degrees in Biomedical Engineering from Vanderbilt University.
Follow Heather A. Brown:
About HeartFlow: HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease.
Juan Jaen
President & Co-Founder of Arcus Biosciences
Juan has been engaged in all aspects of drug discovery and development for more than 30 years. In 2015, he co-founded Arcus Biosciences together with Terry Rosen. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by Bristol-Myers Squibb for $1.25 billion. Previously, he was Chief Scientific Officer and Senior Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Juan led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. At ChemoCentryx, Juan led the discovery efforts for the multi-year collaboration with GSK, which generated over $100M in non-dilutive milestones and fees. From 1996 to 2006, Juan held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then Amgen Inc. (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry. From 1983 to 1996, Juan held various scientific leadership positions at Parke-Davis/Warner-Lambert. Juan holds a Visiting Scholar appointment (ChEM-H) at Stanford University and is a member of the Scientific Advisory Board at Cleave Biosciences. Juan obtained a B.S. degree in Chemistry from Universidad Complutense in Madrid (Spain) and a Ph.D. degree in Organic Chemistry from the University of Michigan. He has co-authored over 100 scientific papers and is an inventor on 50 issued U.S. patents. Juan has been responsible for the advancement of over 20 novel molecules into clinical development for diseases including cancer, Alzheimer’s, Crohn’s, RA, diabetes and diabetic nephropathy, psoriasis, asthma, and vasculitis, among others.
Follow Juan Jaen:
About Arcus Biosciences: Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
Amir Dan Rubin
Chair & CEO & President of One Medical
Amir Dan Rubin is President & CEO at One Medical. As president and chief executive officer, Amir is focused on delivering better health through outstanding, coordinated clinical care; innovative digital technology; and the highest levels of service, access, and engagement. Previously, as EVP and divisional CEO of UnitedHealth Group’s Optum division, he oversaw a number of business lines focused on helping to make the health system work better for everyone. Prior to Optum, Amir was president and CEO of Stanford Health Care where he helped raise patient experience and quality scores to the highest levels in the nation, grow a regional network of care settings, and advance digital health and corporate partnerships in the heart of Silicon Valley. Amir also previously served as COO for the UCLA Health System, and has been awarded the EY Entrepreneur of the Year Award in Northern California in recognition of his role in innovation and industry transformation. He holds MBA and MHSA degrees from the University of Michigan.
Follow Amir Dan Rubin:
About One Medical: One Medical is a members-only technology platform offering an array of concierge medical services.
Lara Abbaschian
Vice President of Lightstone Ventures
Follow Lara Abbaschian:
About Lightstone Ventures: Lightstone Ventures is a leading global venture capital firm.
Jennifer Carter
Vice President, Portfolio Development of McKesson Ventures
Jennifer Carter is the Vice President of Portfolio Development for McKesson Ventures. Jennifer works closely with portfolio companies to help identify and evaluate synergies across the McKesson ecosystem, which includes McKesson’s business units, customers and employee base. In addition, when these synergies create mutual value she helps facilitate efficient execution by acting as a liaison or project manager in order to ensure McKesson Ventures lives up to its value proposition. Jennifer brings over 15 years of experience from various roles across the McKesson enterprise. Jennifer holds a B.S. in Economics from Boston College. Although born and raised in San Francisco, Jennifer spends harvest season on the family farm cultivating pluots and disrupting the plum and apricot industries.
Follow Jennifer Carter:
About McKesson Ventures, McKesson Ventures: McKesson Ventures is a California-based venture capital that focuses on the healthcare industry.
Paul F. Truex
President & CEO, Director of Anthera Pharmaceuticals
Mr. Truex has served as Director, President and Chief Executive Officer since the inception of Anthera in 2004.He was responsible for negotiating Anthera’s product license for A-623, our anti-BAFF peptibody program from Amgen.Prior to founding Anthera Pharmaceuticals, Mr. Truex served as a Founder, Director, President and CEO of Peninsula Pharmaceuticals.During that time Mr. Truex raised over $81 million of institutional capital (including $21 million from a strategic partner) and negotiated both of Peninsula’s product agreements with Shionogi & Co., Ltd. (Doribax®, doripenem) and Takeda Chemical Industries (Teflaro®, ceftaroline). Peninsula was acquired by Johnson and Johnson in April of 2005 for $245 million in an all cash transaction.The remaining entity, Cerexa was subsequently acquired in 2006 for $480 million in cash.During his career, Mr. Truex has successfully raised over $150 million in venture investments and more than $500 million in various public and private equity and debt offerings including Anthera’s Initial Public Offering in 2010 and Versicor’s IPO in 2000.Mr. Truex has extensive experience in sales’ marketing and business development in several industries including pharmaceuticals, biotechnology, consumer electronics, and telecommunications.Prior to Peninsula, Mr. Truex was Vice President of Commercial Development for Versicor Incorporated (acquired by Pfizer) where he directed early commercial efforts for their infectious disease portfolio and participated in the company’s successful $55 million initial public offering.Prior to joining Versicor, Mr. Truex worked at Eli Lilly and Company where he served in various marketing and sales roles during the launch of three different products for the primary care physician market (Actos®’ Evista®’ and Humalog 75/25®). His business development experience includes the Lilly ICOS LLC joint venture’ two majorproduct divestitures and numerous small research collaborations. While there Mr. Truex also worked with several product teams on various divestiture strategies.Mr. Truex obtained his Masters of Business Administration in Marketing and Finance from Indiana University and a Bachelor of Arts degree in Economics from the University of Waterloo.Mr. Truex is a member of the Board of Directors of Trius Therapeutics, Milestone Pharmaceuticals and Waterloo Pharmaceuticals, Inc.
Follow Paul F. Truex:
About Anthera Pharmaceuticals: Anthera Pharmaceuticals is focused on developing products to treat diseases associated with inflammation and autoimmune diseases.
Curtis Scribner
Vice President, Regulatory of Eiger BioPharmaceuticals
Dr. Scribner has more than 25 years of drug development and regulatory affairs experience. He spent 11 years at the FDA in the Center for Biologics as a medical officer with wide experience reviewing non-clinical, CMC, clinical, and IND/BLA regulatory systems, including 2.5 years as the Deputy Director of the Office of Blood. He also was the Senior Regulatory Consultant for Quintiles Consulting, Chief Regulatory Office for Intarcia Therapeutics and he is now the Senior Vice President for Medical and Regulatory Affairs for RRD International. Dr. Scribner is a board certified Internist with post-doctorial training in Immunology and Rheumatology at the NIH.
Follow Curtis Scribner:
About Eiger BioPharmaceuticals, QED Therapeutics: Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.
Kevin Kaster
Vice President, Patents and Licensing of Eiger BioPharmaceuticals
Kevin Kaster has 20 years of experience in biotechnology and large pharma with an established track record of developing effective patent and licensing strategies for important technologies and drug products.Kevin Kaster most recently served as Vice President Corporate Development for Threshold Pharmaceuticals, a public company focused on developing anti-cancer agents. Previously, Kaster was Vice President Intellectual Property for Kosan Biosciences, a public company acquired by BMS in 2008 with geldanamycin and epothilone anti-cancer agents. Kaster also previously managed the patent portfolios of Geron Corporation (telomerase and human embryonic stem cell technologies) and Affymax/Affymetrix (combinatorial chemistry and DNA chip technologies) as well as the PCR technology patent portfolio of Cetus Corporation. Kaster began his career at Eli Lilly and Company, first as a research scientist and then as a patent technician.Kevin Kaster is a graduate of the Indiana University School of Law and a graduate of Vanderbilt University with a BS in Chemistry and Molecular Biology.
Follow Kevin Kaster:
About Eiger BioPharmaceuticals, Lygos: Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.
David Cory
President and Chief Executive Officer, Board Director of Eiger BioPharmaceuticals
David Cory is an entrepreneur and industry veteran with 25-years experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational, transactional, and financial success.Mr. Cory is currently the President and CEO of Eiger BioPharmaceuticals since 2008. He is responsible for negotiating Eiger’s multiple product licenses from Merck and Astra Zeneca. Cory was previously President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS specialty pharmaceutical company, which was acquired by Biovail Pharmaceuticals for $160 million in 2008. Cory was Co-Founder and Chief Commercial Officer at CoTherix, an Orphan Pulmonary Hypertension company, which was acquired by Actelion for $425 million in 2006. Cory began his start up career as Senior Vice President of Commercial Operations at InterMune, a public biotechnology company focused on developing Orphan products for Idiopathic Pulmonary Fibrosis. He was as a key executive in the InterMune IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. Mr. Cory spent the first 12 years of his career in operating positions of increasing responsibility at The Upjohn Company, Glaxo, Glaxo Wellcome, and Glaxo Smith Kline leading teams in CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, where he directed 10 pharmaceutical product launches and the commercialization of 20 brands.David Cory is a graduate of the University of Cincinnati, College of Pharmacy, is board certified in Pharmacy, and holds a Masters Degree in Business Administration from the University of Maryland.
Follow David Cory:
About Eiger BioPharmaceuticals: Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.
Shelly Xiong
Vice President, Regulatory Affairs of Eiger BioPharmaceuticals
Shelly Xiong has over 20 years of pharmaceutical industry experience in virology, clinical development, and regulatory affairs spanning Asia, Europe, and North America. Dr. Xiong most recently served as Director of Regulatory Affairs at InterMune where she was responsible for establishing and managing the product labeling function for European and Canadian commercialization and US labeling preparation for Esbriet NDA for Idiopathic Pulmonary Fibrosis. Previously, she served as Director of China Operations at Covance in Shanghai, responsible for business strategy, client and goverment interactions. Dr. Xiong was at Gilead for 15 years, where she held positions in Clinical Virology and Regulatory Affairs, leading the clinical virology development program for Hepsera for HBV from Phase 2 through product approval. She was involved in multiple IND and NDA filings as well as commercial product labeling for antiviral programs in the US with FDA and in China with CFDA while at Gilead. Dr. Xiong has extensive experience in drug discovery and development in viral diseases including HBV, HCV, HIV, and CMV. She is an author on over 30 publications in scientific journals and publications. Dr. Xiong received her Ph.D. in Biochemistry from University of Wisconsin-Madison and B.S. in Chemistry from Beijing University.
Follow Shelly Xiong:
About Eiger BioPharmaceuticals: Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.
William Brody
President of Salk Institute for Biological Studies
William Brody is the President of the Salk Institute.
Follow William Brody:
About National Academy of Engineering, Salk Institute for Biological Studies: Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology.
Rebecca Newman
Vice President of External Relations of Salk Institute for Biological Studies
Rebecca Newman joined the Salk Institute as the Vice President, External Relations in February 2008. Since her arrival, the Institute has enjoyed an annual net increase in event profits, a historic fundraising cycle and exciting new experiences with unique events such as Chihuly at the Salk, Step into Discovery, the Salk Science and Music Series and Symphony at Salk. In her oversight of fundraising programs, donor relations, and communications, the Institute’s visibility, awareness and community involvement have developed dramatically. In addition, Ms. Newman has led her team to increase private giving by approximately 40 percent over the last four years. She has overseen Salk’s first major fundraising campaign, with a goal of raising $300 million to support scientific research. Newman brings more than 25 years of financial endowment development and capital campaign experience from the business and nonprofit industries. She joined Salk after serving for seven years at the University of California, San Diego, as Associate Vice Chancellor, Development. In this role, she executed a historic conclusion of UCSD’s capital campaign by exceeding its $1 billion goal. She has a long history of volunteerism in the philanthropic community, serving as national president of the United Jewish Communities and National Chair for the United Jewish Appeal Women’s Campaign. Locally, she was campaign chair and president of the United Jewish Federation of San Diego, and a former board member of the Jewish Community Foundation and the San Diego National Bank Business Advisory Council. As a volunteer, she helped design, fund and implement welfare and relief programs in countries as diverse as Argentina, Cuba, Israel, and the republics of the former Soviet Union. A native of Chicago, Rebecca Newman has a bachelor’s degree in history and political science from the University of Michigan.
Follow Rebecca Newman:
About Salk Institute for Biological Studies: Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology.
